MarginsXMarginsX
Home › Markets › Health Care › SRPT

Sarepta Therapeutics Inc. Common Stock (DE) (SRPT)

SRPT trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$15.13
-5.85% on the day
Market cap
$1.6B
Small cap
Revenue · 2025
$2.2B
+15.6% on 2024
Net income · 2025
-$713.4M
-32.5% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/873303/000119312526084144/0001193125-26-084144-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerSRPT on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0000873303
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$2.2B
Net income-$713.4M
Operating income-$699.8M
Net margin-32.5%
Operating margin-31.8%
Revenue growth+15.6%
Cash$801.3M
Total assets$3.3B
P/E (computed)Net income was not positive
P/S (computed)0.7×

Warning signs

Cash runway
Cash-flow positive
$472.8M cash at September 30, 2026
Share count, 1 year
+2.3%
2025-10-31 to 2026-11-02 · +14.6% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
-$417K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$472.8M cash; operating cash flow $46.4M a quarter.Report 2026-09-30
Shares outstanding107,235,848 (2026-11-02); 104,787,187 a year earlier; 93,546,681 three years earlier.Cover page 2026-11-02
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-03-27
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $417K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$381.4M-$28.5M$60.0M$472.8M$857.4M$2.0B10-Q 2026-11-05
Q2 2026
2026-06-30
$401.3M-$4.9M$197.1M$571.1M$847.6M$2.0B10-Q 2026-08-05
Q1 2026
2026-03-31
$730.8M$331.0M-$202.7M$464.4M$838.2M$2.2B10-Q 2026-05-06
Q4 2025
2025-12-31
$442.9M-$412.2M$131.2M$801.3M$829.0M$2.2B10-K 2026-03-02
Q3 2025
2025-09-30
$399.4M-$50.6M-$14.6M$613.1M$140.5M$2.4B10-Q 2026-11-05
Q2 2025
2025-06-30
$611.1M$196.9M$261.3M$510.6MNo debt tags$2.5B10-Q 2026-08-05
Q1 2025
2025-03-31
$744.9M-$447.5M-$583.4M$240.9MNo debt tags$2.2B10-Q 2026-05-06
Q4 2024
2024-12-31
$658.4M$159.0M$92.0M$1.1B$1.1B$1.9B10-K 2026-03-02

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2025-03-03
Latest annual report10-K2026-03-02
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-05
Latest proxyDEFA14A2026-04-24

Source: SEC EDGAR submissions feed, 1,003 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-9.8%
1 month-2.7%
3 months-12.8%
Year to date-25.3%
1 year-9.8%
From 52-week high-32.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
RAREUltragenyx Pharmaceutical Inc.$15.90-1.12%$1.6B
KLRAKailera Therapeutics Inc.$12.57-5.28%$1.6B
ANIPANI Pharmaceuticals Inc.$70.89-0.77%$1.6B
NRIXNurix Therapeutics Inc.$14.73-4.84%$1.6B
ADRXADARx Pharmaceuticals Inc.$14.00-1.41%$1.6B
PGENPrecigen Inc.$4.30-5.29%$1.5B
QUREuniQure N.V.$21.88-8.11%$1.5B
SLSSELLAS Life Sciences Group Inc.$7.47-4.96%$1.5B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier